文献速递泌尿男性生殖肿瘤

纳武利尤单抗联合伊匹木单抗对比舒尼替尼一线治疗晚期肾细胞癌:随机对照3期试验的延长随访疗效与安全性结果

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2019-08-16

在意向治疗人群中同样观察到疗效优势。安全性方面,联合组常见3-4级治疗相关不良事件为脂肪酶升高、淀粉酶升高和ALT升高,舒尼替尼组为高血压、乏力和手足综合征。

要点

  • 联合组客观缓解率42% vs 舒尼替尼29%,中危/高危人群获益一致
  • 联合组3-4级治疗相关不良事件以脂肪酶、淀粉酶和ALT升高为主

核心结论

  • 延长随访显示,纳武利尤单抗联合伊匹木单抗在中危/高危和意向治疗晚期肾细胞癌患者中较舒尼替尼的疗效优势得以维持。
  • 该方案在既往未治疗的晚期肾细胞癌所有风险类别中均显示长期获益。

研究设计与样本

  • 3期、随机、对照、开放标签 CheckMate 214 试验,纳入既往未治疗的晚期或转移性透明细胞肾细胞癌患者。
  • 患者按1:1随机分配至纳武利尤单抗(3 mg/kg 静注)联合伊匹木单抗(1 mg/kg 静注)组或舒尼替尼(50 mg 口服)组。
  • 共1096例患者随机分配(纳武利尤单抗联合伊匹木单抗组550例 vs 舒尼替尼组546例),其中中危/高危患者425例 vs 422例。

关键数值与推荐

  • 联合组最常见的3-4级治疗相关不良事件为脂肪酶升高10%(57/547)、淀粉酶升高6%(31/547)、丙氨酸氨基转移酶升高5%(28/547)。
  • 舒尼替尼组最常见的3-4级治疗相关不良事件为高血压17%(90/535)、乏力10%(51/535)、掌跖红斑感觉异常9%(49/535)。
  • 联合组报告8例治疗相关死亡,舒尼替尼组4例。

临床怎么用

  • 对于既往未治疗的中危/高危晚期肾细胞癌患者,纳武利尤单抗联合伊匹木单抗可作为一线治疗选择,长期随访证实总生存获益。
  • 治疗期间需监测联合方案相关的脂肪酶、淀粉酶和肝酶升高,以及舒尼替尼相关的高血压、乏力和手足综合征。

局限性

  • 本文为延长随访的疗效与安全性报告,非预设的最终分析。
  • 无进展生存和客观缓解由研究者评估,非独立影像评审委员会评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed superior efficacy over sunitinib in patients with previously untreated intermediate-risk or poor-risk advanced renal cell carcinoma, with a manageable safety profile. In this study, we aimed to assess efficacy and safety after extended follow-up to inform the long-term clinical benefit of nivolumab plus ipilimumab versus sunitinib in this setting. METHODS: In the phase 3, randomised, controlled CheckMate 214 trial, patients aged 18 years and older with previously untreated, advanced, or metastatic histologically confirmed renal cell carcinoma with a clear-cell component were recruited from 175 hospitals and cancer centres in 28 countries. Patients were categorised by International Metastatic Renal Cell Carcinoma Database Consortium risk status into favourable-risk, intermediate-risk, and poor-risk subgroups and randomly assigned (1:1) to open-label nivolumab (3 mg/kg intravenously) plus ipilimumab (1 mg/kg intravenously) every 3 weeks for four doses, followed by nivolumab (3 mg/kg intravenously) every 2 weeks; or sunitinib (50 mg orally) once daily for 4 weeks (6-week cycle). Randomisation was done through an interactive voice response system, with a block size of four and stratified by risk status and geographical region. The co-primary endpoints for the trial were overall survival, progression-free survival per independent radiology review committee (IRRC), and objective responses per IRRC in intermediate-risk or poor-risk patients. Secondary endpoints were overall survival, progression-free survival per IRRC, and objective responses per IRRC in the intention-to-treat population, and adverse events in all treated patients. In this Article, we report overall survival, investigator-assessed progression-free survival, investigator-assessed objective response, characterisation of response, and safety after extended follow-up. Efficacy outcomes were assessed in all randomly assigned patients; safety was assessed in all treated patients. This study is registered with ClinicalTrials.gov, number NCT02231749, and is ongoing but now closed to recruitment. FINDINGS: Between Oct 16, 2014, and Feb 23, 2016, of 1390 patients screened, 1096 (79%) eligible patients were randomly assigned to nivolumab plus ipilimumab or sunitinib (550 vs 546 in the intention-to-treat population; 425 vs 422 intermediate-risk or poor-risk patients, and 125 vs 124 favourable-risk patients). With extended follow-up (median follow-up 32·4 months [IQR 13·4-36·3]), in intermediate-risk or poor-risk patients, results for the three co-primary efficacy endpoints showed that nivolumab plus ipilimumab continued to be superior to sunitinib in terms of overall survival (median not reached [95% CI 35·6-not estimable] vs 26·6 months [22·1-33·4]; hazard ratio [HR] 0·66 [95% CI 0·54-0·80], p<0·0001), progression-free survival (median 8·2 months [95% CI 6·9-10·0] vs 8·3 months [7·0-8·8]; HR 0·77 [95% CI 0·65-0·90], p=0·0014), and the proportion of patients achieving an objective response (178 [42%] of 425 vs 124 [29%] of 422; p=0·0001). Similarly, in intention-to-treat patients, nivolumab and ipilimumab showed improved efficacy compared with sunitinib in terms of overall survival (median not reached [95% CI not estimable] vs 37·9 months [32·2-not estimable]; HR 0·71 [95% CI 0·59-0·86], p=0·0003), progression-free survival (median 9·7 months [95% CI 8·1-11·1] vs 9·7 months [8·3-11·1]; HR 0·85 [95% CI 0·73-0·98], p=0·027), and the proportion of patients achieving an objective response (227 [41%] of 550 vs 186 [34%] of 546 p=0·015). In all treated patients, the most common grade 3-4 treatment-related adverse events in the nivolumab and ipilimumab group were increased lipase (57 [10%] of 547), increased amylase (31 [6%]), and increased alanine aminotransferase (28 [5%]), whereas in the sunitinib group they were hypertension (90 [17%] of 535), fatigue (51 [10%]), and palmar-plantar erythrodysaesthesia (49 [9%]). Eight deaths in the nivolumab plus ipilimumab group and four deaths in the sunitinib group were reported as treatment-related. INTERPRETATION: The results suggest that the superior efficacy of nivolumab plus ipilimumab over sunitinib was maintained in intermediate-risk or poor-risk and intention-to-treat patients with extended follow-up, and show the long-term benefits of nivolumab plus ipilimumab in patients with previously untreated advanced renal cell carcinoma across all risk categories. FUNDING: Bristol-Myers Squibb and ONO Pharmaceutical.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019. PMID: 31427204. doi:10.1016/S1470-2045(19)30413-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。